Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study.
Burden of illness
Core diabetes model
Kingdom of Saudi Arabia
Real-world
Saudi Arabia
Type 2 diabetes mellitus
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
19 Jan 2024
19 Jan 2024
Historique:
received:
03
11
2023
accepted:
13
12
2023
medline:
19
1
2024
pubmed:
19
1
2024
entrez:
19
1
2024
Statut:
aheadofprint
Résumé
Type 2 diabetes mellitus (T2DM) is associated with huge clinical and economic burden in the Kingdom of Saudi Arabia (KSA) which can be curtailed by efficacious treatment. In order to achieve this, current treatment pathways for T2DM and associated costs need to be assessed. A longitudinal cohort review was conducted to collect country-specific and patient-specific clinical data, over a minimum observation period of 5 years in the KSA. Patient demographics, clinical characteristics and treatment patterns were recorded. The IQVIA Core Diabetes Model (CDM) version 9.5 Plus was used to assess the burden of illness, which included long-term projections of clinical (life expectancy [LE], quality-adjusted life-years [QALYs], event rates of diabetes-related complications) and direct medical cost (per-patient annual or lifelong [50 years]) outcomes of the most commonly used first-line (1st-line) regimens for T2DM from a payer perspective in the KSA. Data were collected from a subpopulation of 638 patients from 15 participating centres. There was an equal gender representation with a majority of the patients belonging to Arabian/Saudi ethnicity (71.0%). Biguanides (81.5%), sulfonylureas (51.6%), dipeptidyl peptidase 4 (DPP4) inhibitors (26.2%) and fast-acting insulins (17.2%) were the most prescribed 1st-line agents. The most frequently used 1st-line regimens resulted in an estimated LE of 25-28 years, QALYs of 18-21 years and lifelong total cost of illness of 201,377-437,371 Saudi Arabian riyal (53,700-116,632 US dollars). Our study addresses gaps in the current research by providing a complete landscape of baseline demographic, clinical characteristics and treatment patterns from a heterogeneous group of patients with T2DM in the KSA. Additionally, the burden of illness analysis using CDM showed substantially higher cost of T2DM care from a payer perspective in the KSA.
Identifiants
pubmed: 38240948
doi: 10.1007/s12325-023-02772-y
pii: 10.1007/s12325-023-02772-y
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2021. https://diabetesatlas.org/atlas/tenth-edition/?dlmodal=active&dlsrc=https%3A%2F%2Fdiabetesatlas.org%2Fidfawp%2Fresource-files%2F2021%2F07%2FIDF_Atlas_10th_Edition_2021.pdf . Accessed 11 Dec 2023
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11.
pubmed: 32175717
pmcid: 7310804
doi: 10.2991/jegh.k.191028.001
Sherif S, Sumpio BE. Economic development and diabetes prevalence in MENA countries: Egypt and Saudi Arabia comparison. World J Diabetes. 2015;6(2):304–11.
pubmed: 25789111
pmcid: 4360423
doi: 10.4239/wjd.v6.i2.304
Alwakeel JS, Sulimani R, Al-Asaad H, et al. Diabetes complications in 1952 type 2 diabetes mellitus patients managed in a single institution in Saudi Arabia. Ann Saudi Med. 2008;28(4):260–6.
pubmed: 18596402
pmcid: 6074352
doi: 10.5144/0256-4947.2008.260
International Diabetes Federation. Diabetes and cardiovascular disease 2021. https://www.idf.org/our-activities/care-prevention/cardiovascular-disease.html . Accessed 23 May 2023.
Robert AA, Al Dawish MA, Braham R, Musallam MA, Al Hayek AA, Al Kahtany NH. Type 2 diabetes mellitus in Saudi Arabia: major challenges and possible solutions. Curr Diabetes Rev. 2017;13(1):59–64.
pubmed: 26813972
doi: 10.2174/1573399812666160126142605
Almutairi N, Alkharfy KM. Direct medical cost and glycemic control in type 2 diabetic Saudi patients. Appl Health Econ Health Policy. 2013;11(6):671–5.
pubmed: 24174262
doi: 10.1007/s40258-013-0065-6
Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423–30.
pubmed: 28456416
doi: 10.1016/S2213-8587(17)30097-9
Moradi-Lakeh M, El Bcheraoui C, Daoud F, et al. Medication use for chronic health conditions among adults in Saudi Arabia: findings from a national household survey. Pharmacoepidemiol Drug Saf. 2016;25(1):73–81.
pubmed: 26494489
doi: 10.1002/pds.3904
Alzaid A, Ladrón de Guevara P, Beillat M, Lehner Martin V, Atanasov P. Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses. Expert Rev Pharmacoeconom Outcom Res. 2021;21(4):785–98.
doi: 10.1080/14737167.2020.1782748
Alhowaish AK. Economic costs of diabetes in Saudi Arabia. J Family Community Med. 2013;20(1):1–7.
pubmed: 23723724
pmcid: 3663158
doi: 10.4103/2230-8229.108174
Saudi Health Council. Saudi Diabetes Clinical Practice Guidelines (SDCPG), Saudi National Diabetes Center (SNDC) 2021. https://shc.gov.sa/Arabic/Documents/SDCP%20Guidelines.pdf . Accessed 15 May 2023.
Al-Rubeaan K, Banah F, Alruwaily FG, et al. Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study. Curr Med Res Opin. 2023;39(1):27–35.
pubmed: 36342972
doi: 10.1080/03007995.2022.2144052
Al-Rubeaan K, Bana FA, Alruwaily FG, et al. Physicians’ choices in the first- and second-line management of type 2 diabetes in the Kingdom of Saudi Arabia. Saudi Pharm J. 2020;28(3):329–37.
pubmed: 32194335
pmcid: 7078533
doi: 10.1016/j.jsps.2020.01.014
Alramadan MJ, Magliano DJ, Almigbal TH, et al. Glycaemic control for people with type 2 diabetes in Saudi Arabia - an urgent need for a review of management plan. BMC Endocr Disord. 2018;18(1):62.
pubmed: 30200959
pmcid: 6131885
doi: 10.1186/s12902-018-0292-9
McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE Diabetes Model. Value Health. 2014;17(6):714–24.
pubmed: 25236995
doi: 10.1016/j.jval.2014.07.007
Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(S1):S27-40.
pubmed: 15324514
doi: 10.1185/030079904X2006
Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(S1):S5-26.
pubmed: 15324513
doi: 10.1185/030079904X1980
Ramos M, Men P, Wang X, Ustyugova A, Lamotte M. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Eff Resour Alloc. 2021;19(1):46.
pubmed: 34348729
pmcid: 8336098
doi: 10.1186/s12962-021-00299-z
Salem A, Men P, Ramos M, Zhang Y-J, Ustyugova A, Lamotte M. Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with type 2 diabetes in China. J Comparat Effect Res. 2021;10(6):469–80.
doi: 10.2217/cer-2020-0284
Drugs.com. Does metformin cause hypoglycemia? 2021. https://www.drugs.com/medical-answers/metformin-hypoglycemia-3563096/ . Accessed 1 May 2023.
Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Making. 2016;36(8):1020–33.
pubmed: 27553209
pmcid: 5046160
doi: 10.1177/0272989X16658660
Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462–70.
pubmed: 24969008
doi: 10.1016/j.jval.2014.03.003
Foos V, McEwan P. Conversion of hypoglycemia utility decrements from categorical units reflecting event history into event specific disutility scores applicable to diabetes decision models. Value in Health. 2018;21:S223.
doi: 10.1016/j.jval.2018.04.1506
OANDA. Saudi riyal currency. https://www.oanda.com/currency-converter/en/currencies/majors/sar/ . Accessed 11 Dec 2023.
Alzaheb RA, Altemani AH. The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes Metab Syndr Obes. 2018;11:15–21.
pubmed: 29430192
pmcid: 5797462
doi: 10.2147/DMSO.S156214
El Bcheraoui C, Basulaiman M, Tuffaha M, et al. Status of the diabetes epidemic in the Kingdom of Saudi Arabia, 2013. Int J Public Health. 2014;59(6):1011–21.
pubmed: 25292457
doi: 10.1007/s00038-014-0612-4
Hassanein M, Al Awadi FF, El Hadidy KES, et al. The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: an international prospective study (DAR-MENA T2DM). Diabetes Res Clin Pract. 2019;151:275–84.
pubmed: 30825560
doi: 10.1016/j.diabres.2019.02.020
Al Slamah T, Nicholl BI, Alslail FY, Harris L, Kinnear D, Melville CA. Correlates of type 2 diabetes and glycaemic control in adults in Saudi Arabia a secondary data analysis of the Saudi health interview survey. BMC Public Health. 2020;20(1):515.
pubmed: 32303201
pmcid: 7164173
doi: 10.1186/s12889-020-08597-6
AlSlail FY, Akil YA. Treatment patterns, effectiveness, and satisfaction among patients with type 2 diabetes treated with insulin in Saudi Arabia: results of the RIMODIS Study. Diabetes Ther. 2021;12(7):1965–78.
pubmed: 34117593
pmcid: 8266937
doi: 10.1007/s13300-021-01089-9
Mokdad AH, Tuffaha M, Hanlon M, et al. Cost of diabetes in the Kingdom of Saudi Arabia, 2014. J Diabetes Metab. 2015;6(8):575.
Al-Sofiani ME, Batais MA, Aldhafiri E, Alzaid A. Pharmacological treatment of type 2 diabetes in Saudi Arabia: a consensus statement from the Saudi Society of Endocrinology and Metabolism (SSEM). Diabetes Metab Syndr. 2021;15(3):891–9.
pubmed: 33895710
doi: 10.1016/j.dsx.2021.04.003
Alkhatib NS, Almutairi AR, Alkhezi OS, Alfayez OM, Al Yami MS, Almohammed OA. Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. Saudi Pharm J. 2022;30(4):433–9.
pubmed: 35527835
pmcid: 9068523
doi: 10.1016/j.jsps.2022.01.018
Althobaiti FM, Alsanosi SM, Falemban AH, et al. Efficacy and safety of empagliflozin in type 2 diabetes mellitus Saudi patients as add-on to antidiabetic therapy: a prospective, open-label, observational study. J Clin Med. 2022;11(16):4769.
pubmed: 36013008
pmcid: 9410062
doi: 10.3390/jcm11164769
Almigbal TH, Alzarah SA, Aljanoubi FA, et al. Clinical inertia in the management of type 2 diabetes mellitus: a systematic review. Medicina. 2023;59(1):182.
pubmed: 36676805
pmcid: 9866102
doi: 10.3390/medicina59010182
Shafie AA, Gupta V, Baabbad R, Hammerby E, Home P. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2014;106(2):319–27.
pubmed: 25305133
doi: 10.1016/j.diabres.2014.08.024
Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ. 2015;18(4):263–72.
pubmed: 25426701
doi: 10.3111/13696998.2014.991791
Ehlers LH, Lamotte M, Ramos MC, et al. The cost-effectiveness of subcutaneous semaglutide versus empagliflozin in type 2 diabetes uncontrolled on metformin alone in Denmark. Diabetes Ther. 2022;13(3):489–503.
pubmed: 35187628
pmcid: 8934846
doi: 10.1007/s13300-022-01221-3
Evans M, Berry S, Malkin SJP, Hunt B, Sharma A. Evaluating the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.8 mg: a health economic analysis in the UK. Diabetes Ther. 2023;14(6):1005–21.
pubmed: 37120480
pmcid: 10203087
doi: 10.1007/s13300-023-01408-2
Franch-Nadal J, Malkin SJP, Hunt B, Martín V, Gallego Estébanez M, Vidal J. The cost-effectiveness of oral semaglutide in Spain: a long-term health economic analysis based on the PIONEER clinical trials. Adv Ther. 2022;39(7):3180–98.
pubmed: 35553372
doi: 10.1007/s12325-022-02156-8
Shao H, Alsaleh AJO, Dex T, Lew E, Fonseca V. Cost-effectiveness of iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes suboptimally controlled by basal insulin in the US. Diabetes Ther. 2022;13(9):1659–70.
pubmed: 35930188
pmcid: 9399315
doi: 10.1007/s13300-022-01300-5
Charokopou M, Sabater FJ, Townsend R, Roudaut M, McEwan P, Verheggen BG. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. Curr Med Res Opin. 2016;32(2):207–18.
pubmed: 26473650
doi: 10.1185/03007995.2015.1102722
Ali SN, Dang-Tan T, Valentine WJ, Hansen BB. Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the United States. Adv Ther. 2020;37(2):869–82.
pubmed: 31925649
pmcid: 7004420
doi: 10.1007/s12325-019-01199-8
Foos V, Wang K, McEwan P, et al. Assessing the burden of type 2 diabetes in China considering the current status-quo management and implications of improved management using a modeling approach. Value Health Regional Issues. 2019;18:36–46.
doi: 10.1016/j.vhri.2018.08.006
Bain SC, Bekker Hansen B, Hunt B, Chubb B, Valentine WJ. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. J Med Econ. 2020;23(1):98–105.
pubmed: 31311364
doi: 10.1080/13696998.2019.1645018
Hellgren M, Svensson AM, Franzén S, et al. The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: a health economic modelling analysis based on nationwide data. Diabetes Obes Metab. 2021;23(7):1604–13.
pubmed: 33729661
pmcid: 8360155
doi: 10.1111/dom.14376
IMS Institute for Healthcare Informatics. Improving type 2 diabetes therapy compliance and persistence in the Kingdom of Saudi Arabia. How to address avoidable economic and societal Burden. 2016. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/diabetes-reports/improving-type-2-diabetes-therapy-compliance-and-persistence-in-the-kingdom-of-saudi-arabia.pdf . Accessed 15 May 2023.
Social Security Administration. Actuarial Life Table 2020. https://www.ssa.gov/oact/STATS/table4c6.html . Accessed 30 May 2023.
Gregg EW, Zhuo X, Cheng YJ, Albright AL, Narayan KV, Thompson TJ. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabet Endocrinol. 2014;2(11):867–74.
doi: 10.1016/S2213-8587(14)70161-5
Javanbakht M, Baradaran HR, Mashayekhi A, et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS ONE. 2011;6(10):e26864.
pubmed: 22066013
pmcid: 3204988
doi: 10.1371/journal.pone.0026864
Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45(3):253–61.
pubmed: 23953350
doi: 10.1016/j.amepre.2013.04.017
Boutayeb A, Boutayeb W, Lamlili ME, Boutayeb S. Estimation of the direct cost of diabetes in the Arab region. Mediterr J Nutr Metab. 2014;7(1):21–32.
doi: 10.3233/MNM-140002